Dear Editor,

We appreciate the highly time-appropriate information presented in the article "Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China" by Wang et al. \[[@B1]\]. COVID-19 (coronavirus disease) is a newly emerged pandemic caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As a close relative of other epidemic coronaviruses (SARS and Middle East Respiratory Syndrome), SARS-CoV-2 is highly contagious and exhibits flu-like symptoms with pneumonic illness \[[@B1]\]. Although 85% of patients recover from infection without needing hospitalization, elderly people and people with another condition that compromises the immune system such as hypertension or diabetes appear to develop serious illness \[[@B1], [@B2]\]. Detection of viral RNA in urine and kidney tissue of SARS-CoV-2-infected patients indicates the kidney as a target of infection \[[@B2]\]. Several of the recent reviews have mentioned kidney manifestations of COVID-19 \[[@B3], [@B4]\]. While angiotensin-converting enzyme 2 (ACE2) receptors are the functional receptor for the SARS coronavirus, their presentation in the lower respiratory tract, kidney, duodenum, and small intestine might provide possible routes of entry for the SARS-CoV \[[@B5]\]. Studies in a mouse model of SARS-CoV infection demonstrated that ACE2 expression is vital for viral entry and ACE2 overexpression is directly proportional to disease severity \[[@B6]\]. As bradykinin B1 receptor mediates the cross talk between ACE2 and the kinin-kallikrein system in setting the inflammation, selective bradykinin B1 receptor blockers could be used as a promising agent to prevent tissue inflammation during CO­VID-19 infection \[[@B7]\].

Significant functional impairment of the kidney in COVID-19 patients \[[@B8], [@B9]\] is well known, and we see that in our patients frequently. Development of acute kidney injury (AKI) is also associated with significant increased mortality during hospital stay \[[@B9]\]. AKI can be a surrogate for multi-organ failure and serves as a negative prognostic factor for survival in COVID-19 patients \[[@B10]\].

We wonder whether the incidence of AKI by reporting time, and not the total incidence of AKI, was reported in this study by Wang et al. \[[@B1]\] They report that as of February 13, 2020, 7 (6.03%) acute respiratory distress syndrome patients transferred to ICU died of respiratory failure. This is much lower than the overall mortality of more than 52% reported for acute respiratory distress syndrome in COVID-19 patients from Wuhan \[[@B10]\]. We suspect the same methodologic problem underlies the underestimation of AKI in COVID-19 in his study. Therefore, larger studies in this regard are necessary.
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